1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
CIS PROLINE - PRO 75
Clore, G.M.
Qin, J.
Gronenborn, A.M.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
H2 O
18.015
WATER
non-polymer
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
UK
Structure
STRUE6
2005
0969-2126
3
289
297
10.1016/S0969-2126(01)00159-9
7788295
Solution structure of human thioredoxin in a mixed disulfide intermediate complex with its target peptide from the transcription factor NF kappa B.
1995
10.2210/pdb1mdj/pdb
pdb_00001mdj
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
11592.125
THIOREDOXIN
1
man
polymer
1557.755
TARGET SITE IN HUMAN NFKB
1
man
polymer
18.015
water
6
nat
water
no
no
MVKQIESKTAFQEALDAAGDKLVVVDFSATWCGPAKMIKPFFHSLSEKYSNVIFLEVDVDDAQDVASEAEVKATPTFQFF
KKGQKVGEFSGANKEKLEATINELV
MVKQIESKTAFQEALDAAGDKLVVVDFSATWCGPAKMIKPFFHSLSEKYSNVIFLEVDVDDAQDVASEAEVKATPTFQFF
KKGQKVGEFSGANKEKLEATINELV
A
polypeptide(L)
no
no
FRFRYVCEGPSHG
FRFRYVCEGPSHG
B
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
human
Homo
sample
9606
Homo sapiens
database_2
pdbx_database_status
pdbx_struct_assembly
pdbx_struct_oper_list
struct_ref_seq_dif
repository
Initial release
Version format compliance
Version format compliance
Database references
Derived calculations
Other
1
0
1995-06-03
1
1
2008-03-24
1
2
2011-07-13
1
3
2022-02-23
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_database_status.process_site
_struct_ref_seq_dif.details
Y
BNL
1995-02-27
REL
HOH
water
AT POSITION 74 THR WAS FOUND BY WOLMAN ET AL., JOURNAL OF
BIOCHEMISTRY 263, 15506 (1988).
30
THE 3D STRUCTURE OF THE HUMAN THIOREDOXIN-NFKB PEPTIDE
COMPLEX IN SOLUTION BY NMR IS BASED ON 3213 EXPERIMENTAL
RESTRAINTS COMPRISING:
2546 STRUCTURE USEFUL INTERPROTON DISTANCE RESTRAINTS
36 RESTRAINTS FOR 18 BACKBONE H-BONDS
44 RESTRAINTS FOR 6 BOUND WATER MOLECULES
300 TORSION ANGLE RESTRAINTS (104 PHI, 76 PSI, 78 CHI1
AND 31 CHI2 FOR HUMAN THIOREDOXIN, AND 7 CHI1 AND 4
CHI2 RESTRAINTS FOR THE NFKB PEPTIDE)
88 HN-HALPHA THREE-BOND COUPLING CONSTANTS
102 13CALPHA AND 97 13CB CHEMICAL SHIFT RESTRAINTS.
THE BREAKDOWN OF THE INTERPROTON DISTANCE RESTRAINTS IS AS
FOLLOWS:
INTRAMOLECULAR HTRX RESTRAINTS:
503 SEQUENTIAL
437 SHORT RANGE (1 < |I-J|<=5)
727 LONG RANGE (|I-J|>5)
690 INTRARESIDUE
INTRAMOLECULAR PEPTIDE RESTRAINTS: 115
INTERMOLECULAR HTRX-NFKB: 74
THE STRUCTURES ARE CALCULATED USING THE HYBRID METRIC
MATRIX DISTANCE GEOMETRY-DYNAMICAL SIMULATED ANNEALING
METHOD DESCRIBED BY: NILGES, M., CLORE, G.M. &
GRONENBORN, A.M. (1988) FEBS LETT 229, 317 - 324. ALL
STRUCTURAL STATISTICS ARE GIVEN IN THE REFERENCE.
THE STRUCTURE FOUND IN PDB ENTRY 1MDI IS THE RESTRAINED
MINIMIZED AVERAGE STRUCTURE: (SA)R. THIS IS OBTAINED
BY FIRST AVERAGING THE COORDINATES OF THE INDIVIDUAL 60
DYNAMICAL SIMULATED ANNEALING SA STRUCTURES BEST FITTED TO
RESIDUES 1 - 105 OF HTRX AND RESIDUES 57 - 67 OF THE
PEPTIDE AND SUBJECTING THE RESULTING COORDINATES TO
RESTRAINED MINIMIZATION. THE LAST NUMBER COLUMN IN THIS
SET OF COORDINATES (THE B-FACTOR COLUMN IN X-RAY
STRUCTURES) GIVES THE AVERAGE RMS DIFFERENCE BETWEEN THE
INDIVIDUAL SA STRUCTURES AND THE MEAN STRUCTURE. THE
NUMBERS IN THE LAST COLUMN OF THE INDIVIDUAL STRUCTURES
HAVE NO MEANING.
HOH
1
3
HOH
HOH
106
A
HOH
2
3
HOH
HOH
107
A
HOH
3
3
HOH
HOH
108
A
HOH
4
3
HOH
HOH
109
A
HOH
5
3
HOH
HOH
110
A
HOH
6
3
HOH
HOH
111
A
MET
1
n
1
MET
1
A
VAL
2
n
2
VAL
2
A
LYS
3
n
3
LYS
3
A
GLN
4
n
4
GLN
4
A
ILE
5
n
5
ILE
5
A
GLU
6
n
6
GLU
6
A
SER
7
n
7
SER
7
A
LYS
8
n
8
LYS
8
A
THR
9
n
9
THR
9
A
ALA
10
n
10
ALA
10
A
PHE
11
n
11
PHE
11
A
GLN
12
n
12
GLN
12
A
GLU
13
n
13
GLU
13
A
ALA
14
n
14
ALA
14
A
LEU
15
n
15
LEU
15
A
ASP
16
n
16
ASP
16
A
ALA
17
n
17
ALA
17
A
ALA
18
n
18
ALA
18
A
GLY
19
n
19
GLY
19
A
ASP
20
n
20
ASP
20
A
LYS
21
n
21
LYS
21
A
LEU
22
n
22
LEU
22
A
VAL
23
n
23
VAL
23
A
VAL
24
n
24
VAL
24
A
VAL
25
n
25
VAL
25
A
ASP
26
n
26
ASP
26
A
PHE
27
n
27
PHE
27
A
SER
28
n
28
SER
28
A
ALA
29
n
29
ALA
29
A
THR
30
n
30
THR
30
A
TRP
31
n
31
TRP
31
A
CYS
32
n
32
CYS
32
A
GLY
33
n
33
GLY
33
A
PRO
34
n
34
PRO
34
A
ALA
35
n
35
ALA
35
A
LYS
36
n
36
LYS
36
A
MET
37
n
37
MET
37
A
ILE
38
n
38
ILE
38
A
LYS
39
n
39
LYS
39
A
PRO
40
n
40
PRO
40
A
PHE
41
n
41
PHE
41
A
PHE
42
n
42
PHE
42
A
HIS
43
n
43
HIS
43
A
SER
44
n
44
SER
44
A
LEU
45
n
45
LEU
45
A
SER
46
n
46
SER
46
A
GLU
47
n
47
GLU
47
A
LYS
48
n
48
LYS
48
A
TYR
49
n
49
TYR
49
A
SER
50
n
50
SER
50
A
ASN
51
n
51
ASN
51
A
VAL
52
n
52
VAL
52
A
ILE
53
n
53
ILE
53
A
PHE
54
n
54
PHE
54
A
LEU
55
n
55
LEU
55
A
GLU
56
n
56
GLU
56
A
VAL
57
n
57
VAL
57
A
ASP
58
n
58
ASP
58
A
VAL
59
n
59
VAL
59
A
ASP
60
n
60
ASP
60
A
ASP
61
n
61
ASP
61
A
ALA
62
n
62
ALA
62
A
GLN
63
n
63
GLN
63
A
ASP
64
n
64
ASP
64
A
VAL
65
n
65
VAL
65
A
ALA
66
n
66
ALA
66
A
SER
67
n
67
SER
67
A
GLU
68
n
68
GLU
68
A
ALA
69
n
69
ALA
69
A
GLU
70
n
70
GLU
70
A
VAL
71
n
71
VAL
71
A
LYS
72
n
72
LYS
72
A
ALA
73
n
73
ALA
73
A
THR
74
n
74
THR
74
A
PRO
75
n
75
PRO
75
A
THR
76
n
76
THR
76
A
PHE
77
n
77
PHE
77
A
GLN
78
n
78
GLN
78
A
PHE
79
n
79
PHE
79
A
PHE
80
n
80
PHE
80
A
LYS
81
n
81
LYS
81
A
LYS
82
n
82
LYS
82
A
GLY
83
n
83
GLY
83
A
GLN
84
n
84
GLN
84
A
LYS
85
n
85
LYS
85
A
VAL
86
n
86
VAL
86
A
GLY
87
n
87
GLY
87
A
GLU
88
n
88
GLU
88
A
PHE
89
n
89
PHE
89
A
SER
90
n
90
SER
90
A
GLY
91
n
91
GLY
91
A
ALA
92
n
92
ALA
92
A
ASN
93
n
93
ASN
93
A
LYS
94
n
94
LYS
94
A
GLU
95
n
95
GLU
95
A
LYS
96
n
96
LYS
96
A
LEU
97
n
97
LEU
97
A
GLU
98
n
98
GLU
98
A
ALA
99
n
99
ALA
99
A
THR
100
n
100
THR
100
A
ILE
101
n
101
ILE
101
A
ASN
102
n
102
ASN
102
A
GLU
103
n
103
GLU
103
A
LEU
104
n
104
LEU
104
A
VAL
105
n
105
VAL
105
A
PHE
1
n
1
PHE
1
B
ARG
2
n
2
ARG
2
B
PHE
3
n
3
PHE
3
B
ARG
4
n
4
ARG
4
B
TYR
5
n
5
TYR
5
B
VAL
6
n
6
VAL
6
B
CYS
7
n
7
CYS
7
B
GLU
8
n
8
GLU
8
B
GLY
9
n
9
GLY
9
B
PRO
10
n
10
PRO
10
B
SER
11
n
11
SER
11
B
HIS
12
n
12
HIS
12
B
GLY
13
n
13
GLY
13
B
author_defined_assembly
2
dimeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
A
O
LYS
3
A
O
LYS
3
A
N
PHE
54
A
N
PHE
54
A
O
ILE
53
A
O
ILE
53
A
N
VAL
24
A
N
VAL
24
A
O
VAL
23
A
O
VAL
23
A
N
PHE
80
A
N
PHE
80
A
O
PHE
77
A
O
PHE
77
A
N
PHE
89
A
N
PHE
89
2
A
A
H
H2
ASP
HOH
60
108
1.32
5
A
A
H
H2
ASP
HOH
60
108
1.14
10
A
A
H
H2
LEU
HOH
22
111
1.34
11
A
A
H
H2
LEU
HOH
22
111
1.26
12
A
A
H
H1
ASP
HOH
60
108
1.32
13
A
A
H
H2
LEU
HOH
22
111
1.30
15
A
A
H
H2
LYS
HOH
82
106
1.31
23
A
A
H
H1
ASP
HOH
60
108
1.29
23
A
A
H
H2
LEU
HOH
22
111
1.32
26
A
A
H
H2
ASP
HOH
60
108
1.30
1
A
SER
28
-110.51
-162.67
1
A
PHE
41
-110.10
-76.94
1
A
SER
90
-102.77
-169.70
1
A
ALA
92
-57.01
94.35
1
B
ARG
4
-142.08
-105.00
1
B
TYR
5
-109.74
-169.81
1
B
GLU
8
-83.17
44.63
1
B
PRO
10
-67.33
25.76
1
B
HIS
12
-58.63
-94.79
2
A
PRO
40
-59.68
-8.16
2
A
PHE
41
-108.19
-70.30
2
A
SER
90
-103.97
-163.83
2
A
ALA
92
-53.18
94.36
2
B
ARG
4
-138.70
-86.48
2
B
GLU
8
-83.92
45.00
2
B
PRO
10
-66.47
22.99
3
A
SER
28
-107.33
-162.46
3
A
PHE
41
-108.77
-78.23
3
A
LEU
45
-49.74
-13.27
3
A
LYS
82
56.55
17.19
3
A
SER
90
-103.36
-167.95
3
A
ALA
92
-56.28
96.44
3
B
ARG
2
-164.27
62.64
3
B
ARG
4
-145.69
-110.43
3
B
GLU
8
-83.25
47.57
3
B
PRO
10
-68.38
26.94
4
A
PHE
41
-111.20
-80.61
4
A
VAL
59
-52.06
-0.58
4
A
GLU
88
-173.71
147.45
4
A
SER
90
-102.76
-167.88
4
A
ALA
92
-60.81
95.11
4
B
ARG
2
-167.74
21.92
4
B
ARG
4
-150.68
-105.27
4
B
GLU
8
-83.00
44.18
4
B
PRO
10
-66.34
23.13
4
B
HIS
12
-156.17
-122.04
5
A
PHE
41
-103.54
-70.21
5
A
VAL
59
-56.87
-2.06
5
A
ALA
92
-56.55
94.69
5
B
ARG
4
-149.17
-93.20
5
B
TYR
5
-116.03
-166.29
5
B
GLU
8
-84.54
42.91
5
B
PRO
10
-66.39
24.36
6
A
PHE
41
-110.39
-72.19
6
A
VAL
59
-54.14
-6.86
6
A
SER
90
-103.07
-163.70
6
A
ALA
92
-53.09
94.53
6
B
ARG
4
-150.23
-99.88
6
B
GLU
8
-82.97
46.01
6
B
PRO
10
-68.24
25.52
7
A
PHE
41
-113.57
-70.36
7
A
LYS
82
58.19
19.79
7
A
SER
90
-103.04
-161.45
7
A
ALA
92
-53.64
98.94
7
B
ARG
4
-148.15
-104.27
7
B
TYR
5
-112.23
-167.53
7
B
GLU
8
-82.63
42.95
7
B
PRO
10
-70.76
24.70
7
B
HIS
12
-55.58
-80.89
8
A
SER
28
-105.05
-164.52
8
A
PHE
41
-103.16
-71.57
8
A
SER
90
-103.15
-167.29
8
A
ALA
92
-55.10
93.61
8
B
ARG
2
-147.07
55.01
8
B
ARG
4
-150.54
-110.25
8
B
GLU
8
-82.84
46.71
8
B
PRO
10
-67.45
24.99
9
A
PHE
41
-103.00
-70.51
9
A
VAL
59
-55.77
-9.90
9
A
ALA
92
-50.50
97.07
9
B
ARG
4
-150.49
-102.07
9
B
GLU
8
-83.57
42.82
9
B
PRO
10
-66.53
24.55
9
B
HIS
12
-65.40
-148.71
10
A
PHE
41
-111.04
-77.60
10
A
VAL
59
-54.39
-2.69
10
A
SER
90
-102.42
-163.04
10
A
ALA
92
-52.58
96.78
10
B
ARG
2
-159.13
61.96
10
B
ARG
4
-150.29
-102.92
10
B
GLU
8
-83.63
45.79
10
B
PRO
10
-66.30
22.68
11
A
PHE
41
-103.48
-71.78
11
A
VAL
59
-58.93
-2.85
11
A
SER
90
-103.40
-168.72
11
A
ALA
92
-51.49
97.56
11
B
ARG
4
-141.97
-84.40
11
B
TYR
5
-125.31
-169.39
11
B
GLU
8
-83.37
44.51
11
B
PRO
10
-67.98
25.73
11
B
HIS
12
-160.72
-61.27
12
A
SER
28
-108.72
-164.75
12
A
PHE
41
-103.62
-69.83
12
A
SER
90
-101.69
-161.78
12
A
ALA
92
-56.15
99.15
12
B
ARG
2
-152.01
62.03
12
B
ARG
4
-144.53
-102.90
12
B
GLU
8
-83.20
44.42
12
B
PRO
10
-67.58
24.87
12
B
HIS
12
51.54
-92.30
13
A
PHE
41
-111.19
-72.60
13
A
VAL
59
-59.07
-2.94
13
A
SER
90
-102.51
-160.77
13
A
ALA
92
-56.65
89.99
13
B
ARG
2
-171.53
78.27
13
B
ARG
4
-150.45
-108.53
13
B
GLU
8
-83.74
44.98
13
B
PRO
10
-67.45
20.78
14
A
SER
28
-107.53
-163.73
14
A
PHE
41
-99.67
-69.80
14
A
SER
90
-103.64
-162.49
14
A
ALA
92
-63.57
95.39
14
B
ARG
4
-144.54
-107.87
14
B
GLU
8
-83.70
42.01
14
B
PRO
10
-66.89
21.45
14
B
HIS
12
-165.79
-144.04
15
A
PHE
41
-102.37
-77.67
15
A
SER
90
-103.50
-168.52
15
A
ALA
92
-56.58
95.77
15
B
ARG
4
-145.59
-86.86
15
B
TYR
5
-123.82
-167.01
15
B
GLU
8
-83.14
46.13
15
B
PRO
10
-65.97
18.65
16
A
PHE
41
-104.51
-72.67
16
A
SER
90
-104.31
-167.07
16
A
ALA
92
-58.85
96.96
16
B
ARG
4
-143.06
-99.45
16
B
GLU
8
-83.87
46.77
16
B
PRO
10
-70.11
26.84
17
A
SER
28
-103.74
-163.89
17
A
PHE
41
-109.69
-77.10
17
A
LEU
45
-49.63
-14.99
17
A
SER
90
-103.61
-165.64
17
A
ALA
92
-53.53
95.68
17
B
ARG
4
-150.24
-81.82
17
B
GLU
8
-82.43
44.72
17
B
PRO
10
-69.65
22.84
18
A
PHE
41
-108.64
-77.23
18
A
VAL
59
-52.05
-9.81
18
A
SER
90
-104.36
-166.99
18
A
ALA
92
-58.15
95.00
18
B
ARG
4
-132.67
-106.88
18
B
GLU
8
-83.31
45.33
18
B
PRO
10
-65.87
20.29
18
B
HIS
12
-161.54
-70.92
19
A
SER
28
-104.88
-164.89
19
A
PHE
41
-110.29
-73.67
19
A
LEU
45
-49.05
-13.10
19
A
SER
90
-103.20
-161.34
19
A
ALA
92
-53.58
98.64
19
B
ARG
2
-169.20
94.48
19
B
ARG
4
-150.71
-110.91
19
B
GLU
8
-83.85
48.71
19
B
PRO
10
-66.48
21.59
20
A
PRO
40
-67.39
0.65
20
A
PHE
41
-119.00
-78.42
20
A
LEU
45
-49.25
-16.72
20
A
VAL
59
-56.94
-0.90
20
A
ALA
62
-108.01
43.26
20
A
LYS
82
57.05
9.42
20
A
SER
90
-102.07
-163.76
20
A
ALA
92
-54.62
97.53
20
B
ARG
4
-150.45
-88.16
20
B
GLU
8
-83.30
49.45
20
B
PRO
10
-66.61
25.57
20
B
HIS
12
51.56
-127.67
21
A
PHE
41
-107.63
-76.51
21
A
ALA
92
-59.87
92.12
21
B
ARG
2
-154.10
69.06
21
B
ARG
4
-143.57
-101.05
21
B
TYR
5
-114.72
-165.43
21
B
GLU
8
-83.80
41.99
21
B
PRO
10
-66.85
25.71
22
A
SER
28
-111.94
-162.21
22
A
PHE
41
-105.97
-73.27
22
A
VAL
59
-59.48
-8.57
22
A
SER
90
-102.29
-164.82
22
A
ALA
92
-54.51
98.85
22
B
ARG
4
-147.41
-101.05
22
B
TYR
5
-117.32
-169.37
22
B
GLU
8
-83.00
46.51
22
B
PRO
10
-68.37
26.32
23
A
SER
28
-103.37
-162.88
23
A
PHE
41
-110.66
-78.02
23
A
LEU
45
-49.39
-16.28
23
A
ALA
92
-53.83
96.72
23
B
ARG
4
-138.07
-108.48
23
B
GLU
8
-82.89
45.49
23
B
PRO
10
-67.31
24.53
24
A
PHE
41
-104.66
-70.12
24
A
SER
90
-107.49
-168.44
24
A
ALA
92
-49.34
92.14
24
B
ARG
4
-144.29
-105.29
24
B
TYR
5
-109.67
-167.21
24
B
GLU
8
-83.43
44.76
24
B
PRO
10
-67.20
24.66
24
B
HIS
12
-168.11
96.64
25
A
PHE
41
-111.88
-74.36
25
A
LEU
45
-49.14
-15.97
25
A
SER
90
-102.58
-167.47
25
A
ALA
92
-58.69
94.05
25
B
ARG
2
-145.58
56.19
25
B
ARG
4
-133.43
-91.17
25
B
GLU
8
-83.93
42.44
25
B
PRO
10
-66.27
20.77
25
B
HIS
12
-46.79
155.50
26
A
PHE
41
-107.69
-75.69
26
A
SER
90
-103.03
-169.75
26
A
ALA
92
-57.08
95.97
26
B
ARG
2
-150.87
72.17
26
B
ARG
4
-147.86
-81.28
26
B
GLU
8
-83.20
44.99
26
B
PRO
10
-67.16
22.73
27
A
PRO
40
-65.55
7.04
27
A
PHE
41
-127.80
-74.51
27
A
LEU
45
-49.49
-16.77
27
A
SER
90
-101.04
-162.47
27
A
ALA
92
-56.20
96.66
27
B
ARG
4
-146.86
-92.66
27
B
TYR
5
-127.22
-169.22
27
B
GLU
8
-82.97
45.89
27
B
PRO
10
-68.41
27.14
28
A
SER
28
-103.05
-164.21
28
A
PHE
41
-111.43
-79.51
28
A
SER
90
-102.59
-161.51
28
A
ALA
92
-59.71
97.33
28
B
ARG
4
-136.17
-79.85
28
B
TYR
5
-129.02
-167.48
28
B
GLU
8
-83.18
47.18
28
B
PRO
10
-69.01
20.93
29
A
PHE
41
-111.46
-78.00
29
A
LEU
45
-49.05
-14.10
29
A
VAL
59
-53.43
-8.90
29
A
SER
90
-102.83
-169.56
29
A
ALA
92
-58.78
96.96
29
B
ARG
2
-157.39
60.21
29
B
ARG
4
-150.99
-112.27
29
B
GLU
8
-82.82
41.80
29
B
PRO
10
-68.07
27.92
30
A
SER
28
-105.55
-164.70
30
A
PHE
41
-104.37
-73.93
30
A
SER
90
-103.38
-162.97
30
A
ALA
92
-58.72
93.29
30
B
ARG
4
-140.72
-102.19
30
B
TYR
5
-109.27
-169.85
30
B
GLU
8
-83.14
46.13
30
B
PRO
10
-67.84
25.35
HIGH RESOLUTION SOLUTION NMR STRUCTURE OF MIXED DISULFIDE INTERMEDIATE BETWEEN HUMAN THIOREDOXIN (C35A, C62A, C69A, C73A) MUTANT AND A 13 RESIDUE PEPTIDE COMPRISING ITS TARGET SITE IN HUMAN NFKB (RESIDUES 56-68 OF THE P50 SUBUNIT OF NFKB)
1
N
N
2
N
N
3
N
N
A
LYS
8
A
LYS
8
HELX_P
A
ALA
17
A
ALA
17
1
1
10
A
GLY
33
A
GLY
33
HELX_P
A
PHE
42
A
PHE
42
1
2
10
A
SER
44
A
SER
44
HELX_P
A
LYS
48
A
LYS
48
5
3
5
A
GLN
63
A
GLN
63
HELX_P
A
ALA
69
A
ALA
69
1
4
7
A
LYS
94
A
LYS
94
HELX_P
A
LEU
104
A
LEU
104
1
5
11
disulf
2.020
A
CYS
32
A
SG
CYS
32
1_555
B
CYS
7
B
SG
CYS
7
1_555
COMPLEX (ELECTRON TRANSPORT/PEPTIDE)
COMPLEX (ELECTRON TRANSPORT-PEPTIDE), COMPLEX (ELECTRON TRANSPORT-PEPTIDE) complex
A
THR
74
A
THR
74
1
A
PRO
75
A
PRO
75
-1.41
A
THR
74
A
THR
74
2
A
PRO
75
A
PRO
75
-2.15
A
THR
74
A
THR
74
3
A
PRO
75
A
PRO
75
-1.27
A
THR
74
A
THR
74
4
A
PRO
75
A
PRO
75
-1.92
A
THR
74
A
THR
74
5
A
PRO
75
A
PRO
75
-2.38
A
THR
74
A
THR
74
6
A
PRO
75
A
PRO
75
-1.59
A
THR
74
A
THR
74
7
A
PRO
75
A
PRO
75
-1.58
A
THR
74
A
THR
74
8
A
PRO
75
A
PRO
75
-1.97
A
THR
74
A
THR
74
9
A
PRO
75
A
PRO
75
-2.03
A
THR
74
A
THR
74
10
A
PRO
75
A
PRO
75
-1.76
A
THR
74
A
THR
74
11
A
PRO
75
A
PRO
75
-1.54
A
THR
74
A
THR
74
12
A
PRO
75
A
PRO
75
-1.71
A
THR
74
A
THR
74
13
A
PRO
75
A
PRO
75
-1.88
A
THR
74
A
THR
74
14
A
PRO
75
A
PRO
75
-1.80
A
THR
74
A
THR
74
15
A
PRO
75
A
PRO
75
-1.84
A
THR
74
A
THR
74
16
A
PRO
75
A
PRO
75
-1.94
A
THR
74
A
THR
74
17
A
PRO
75
A
PRO
75
-1.77
A
THR
74
A
THR
74
18
A
PRO
75
A
PRO
75
-1.42
A
THR
74
A
THR
74
19
A
PRO
75
A
PRO
75
-1.72
A
THR
74
A
THR
74
20
A
PRO
75
A
PRO
75
-1.30
A
THR
74
A
THR
74
21
A
PRO
75
A
PRO
75
-2.19
A
THR
74
A
THR
74
22
A
PRO
75
A
PRO
75
-1.69
A
THR
74
A
THR
74
23
A
PRO
75
A
PRO
75
-1.80
A
THR
74
A
THR
74
24
A
PRO
75
A
PRO
75
-1.81
A
THR
74
A
THR
74
25
A
PRO
75
A
PRO
75
-1.96
A
THR
74
A
THR
74
26
A
PRO
75
A
PRO
75
-2.03
A
THR
74
A
THR
74
27
A
PRO
75
A
PRO
75
-1.63
A
THR
74
A
THR
74
28
A
PRO
75
A
PRO
75
-2.20
A
THR
74
A
THR
74
29
A
PRO
75
A
PRO
75
-1.78
A
THR
74
A
THR
74
30
A
PRO
75
A
PRO
75
-1.78
THIO_HUMAN
UNP
1
1
P10599
VKQIESKTAFQEALDAAGDKLVVVDFSATWCGPCKMIKPFFHSLSEKYSNVIFLEVDVDDCQDVASECEVKCMPTFQFFK
KGQKVGEFSGANKEKLEATINELV
NFKB1_HUMAN
UNP
2
1
P19838
MADDDPYGTGQMFHLNTALTHSIFNAELYSPEIPLSTDGPYLQILEQPKQRGFRFRYVCEGPSHGGLPGASSEKNKKSYP
QVKICNYVGPAKVIVQLVTNGKNIHLHAHSLVGKHCEDGVCTVTAGPKDMVVGFANLGILHVTKKKVFETLEARMTEACI
RGYNPGLLVHSDLAYLQAEGGGDRQLTDREKEIIRQAAVQQTKEMDLSVVRLMFTAFLPDSTGSFTRRLEPVVSDAIYDS
KAPNASNLKIVRMDRTAGCVTGGEEIYLLCDKVQKDDIQIRFYEEEENGGVWEGFGDFSPTDVHRQFAIVFKTPKYKDVN
ITKPASVFVQLRRKSDLETSEPKPFLYYPEIKDKEEVQRKRQKLMPNFSDSFGGGSGAGAGGGGMFGSGGGGGSTGSPGP
GYGYSNYGFPPYGGITFHPGVTKSNAGVTHGTINTKFKNGPKDCAKSDDEESLTLPEKETEGEGPSLPMACTKTEPIALA
STMEDKEQDMGFQDNLFLEKALQLARRHANALFDYAVTGDVKMLLAVQRHLTAVQDENGDSVLHLAIIHLHAQLVRDLLE
VTSGLISDDIINMRNDLYQTPLHLAVITKQEDVVEDLLRVGADLSLLDRWGNSVLHLAAKEGHDRILSILLKSRKAAPLI
DHPNGEGLNAIHIAVMSNSLPCLLLLVAAGAEVNAQEQKSGRTPLHLAVEYDNISLAGCLLLEGDAHVDSTTYDGTTPLH
IAAGRGSTRLAALLKAAGADPLVENFEPLYDLDDSWEKAGEDEGVVPGTTPLDMAANWQVFDILNGKPYEPVFTSDDILP
QGDMKQLTEDTRLQLCKLLEIPDPDKNWATLAQKLGLGILNNAFRLSPAPSKTLMDNYEVSGGTIKELMEALQQMGYTEA
IEVIQAAFRTPATTASSPVTTAQVHCLPLSSSSTRQHIDELRDSDSVCDSGVETSFRKLSFTESLTGDSPLLSLNKMPHG
YGQEGPIEGKI
1
104
1MDJ
2
105
P10599
A
1
2
105
53
65
1MDJ
1
13
P19838
B
2
1
13
1
CYS
conflict
ALA
35
1MDJ
A
P10599
UNP
34
35
1
CYS
conflict
ALA
62
1MDJ
A
P10599
UNP
61
62
1
CYS
conflict
ALA
69
1MDJ
A
P10599
UNP
68
69
1
CYS
conflict
ALA
73
1MDJ
A
P10599
UNP
72
73
1
MET
conflict
THR
74
1MDJ
A
P10599
UNP
73
74
5
parallel
parallel
anti-parallel
anti-parallel
A
VAL
2
A
VAL
2
A
ILE
5
A
ILE
5
A
ILE
53
A
ILE
53
A
VAL
57
A
VAL
57
A
VAL
23
A
VAL
23
A
PHE
27
A
PHE
27
A
THR
76
A
THR
76
A
LYS
81
A
LYS
81
A
GLN
84
A
GLN
84
A
SER
90
A
SER
90
1
P 1